# Torigen Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/torigen-pharmaceuticals

- Industry: Healthcare Specialists
- Headquarters: Farmington, US
- Website: www.torigen.com
- Total disclosed funding: $16M
- Latest round: Series A (Nov 16, 2022)
- Investors on record: 10

## About

Based in Connecticut, US, and founded in 2013, Torigen Pharmaceuticals Inc. operates as a Veterinary pharmaceutical company that develops prescription products for veterinary cancer treatment. The firm as of May 2024, is led by its founder and CEO, Ashley Kalinauskas.

 The company, regulated by the USDA Center for Veterinary Biologics, specializes in developing an experimental autologous prescription product for veterinary cancer. Torigen’s approach involves creating personalized whole-cell tissue vaccines from a pet’s own deactivated tumor cells, aiming to harness the immune system to combat cancer. Torigen’s core product focuses on generating specific adaptive immunity to tumor-associated antigens and its vaccines are applicable to a variety of cancers. These treatments can be administered alone or alongside traditional therapies like chemotherapy and radiation, making them versatile and practical for different clinical settings. As of May 2024, more than 1,200 companion animals have been treated with Torigen’s products.

## Funding rounds

- Series A, Nov 16, 2022, $13M — Advantage Capital, University of Connecticut Foundation, Ironwood Capital, Connecticut Innovations, University of Notre Dame, Emerald Development Managers, SoGal Ventures, Werth Family Investment Associates, Gaingels
- Series A, Feb 7, 2019, $3.1M — Connecticut Innovations
- Seed, Aug 5, 2018 — Everywhere Ventures

## Investors

- Everywhere Ventures (https://capitalatlas.ai/funds/everywhere-ventures) — Seed
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A
- Advantage Capital — Series A
- University of Connecticut Foundation — Series A
- Ironwood Capital (https://capitalatlas.ai/funds/ironwood-capital) — Series A
- University of Notre Dame — Series A
- Emerald Development Managers (https://capitalatlas.ai/funds/emerald-development-managers) — Series A
- SoGal Ventures (https://capitalatlas.ai/funds/sogal-ventures) — Series A
- Werth Family Investment Associates (https://capitalatlas.ai/funds/werth-family-investment-associates) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A